Clinical trial results showed that the mechanism of action of YXTMD in treating CHD with BBS may be related to the activation of the PI3K-AKt signaling pathway, downregulation of GSK-3β, and mediation of lipid-metabolism-based metabolic processes. This evidence concerns the gene PIK3CA and Bardet-Biedl syndrome.